# Inibio Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/inibio-co

- Industry: Healthcare Specialists
- Headquarters: Bucheon, South Korea
- Website: www.inibio.com
- Total disclosed funding: $17M
- Latest round: Series C (May 1, 2021)
- Investors on record: 7

## About

Based in Bucheon, South Korea, and founded in 2017, Inibio Co., Ltd. operates as a company specializing in protein drug development. In February 2022, Inibio Inc. raised KRW 41.5 billion in series B funding from returning investor KUDOS VENTURES Co., Ltd., new investors Kiwoom Securities, NH Hedge Asset Management, Ryukyung PSG Asset Management, and SBI Investment Korea, and other unspecified investors.

The company possesses protein drug platform technology and Botulinum toxin (aka Botox) injection that is undergoing a clinical trial for glabellar wrinkles and is expected to be released after completing domestic clinical trials.

Its pipeline products include cosmeceuticals, medical devices, biopharmaceuticals, natural products, and cosmetics

As of 2022, Inibio Inc. has obtained approval for pharmaceutical manufacturing and quality control and export licenses allowing the company to reach the global markets of the US, Europe, China, and Brazil.

Inibio plans to complete the selection of a listing manager and be listed on the KOSDAQ within 2022.

## Funding rounds

- Series C, May 1, 2021, $11M — SBI Investment Korea, Kiwoom Securities, NH Hedge Asset Management, Ryukyung PSG Asset Management, Kudos Ventures
- Series B, Jun 1, 2019, $5.3M — Korea Technology Finance Corporation, ILDONG PHARMACEUTICAL, Kudos Ventures

## Investors

- Korea Technology Finance Corporation — Series B
- ILDONG PHARMACEUTICAL — Series B
- Kudos Ventures (https://capitalatlas.ai/funds/kudos-ventures) — Series B, Series C
- SBI Investment Korea (https://capitalatlas.ai/funds/sbi-investment-korea) — Series C
- Kiwoom Securities — Series C
- NH Hedge Asset Management — Series C
- Ryukyung PSG Asset Management — Series C